P+P advises vasopharm on financing

January 2016

P+P Pöllath + Partners advised vasopharm GmbH as part of a financing round amounting to EUR 20 million.

Alongside existing investors such as Entrepreneurs Fund, Heidelberg Capital Private Equity, Bayern Kapital and funds advised by Hanseatic Asset Management Ltd., the investor Fort Rock Capital participated in this financing round. The venture partner of Fort Rock Capital, Mario Alberto Accardi, will remain a member of the advisory board of vasopharm GmbH.

vasopharm GmbH, based in Wurzburg, Bavaria, is a biopharmaceutical company focusing on research and development of new treatments for the treatment of cerebral and cardiovascular diseases and their symptoms. The company's core competence lies in the development of active ingredients for controlling nitric oxide levels by modulation of NO synthases.

Munich-based P+P partner Michael Inhester advised vasopharm GmbH on corporate and financing issues.